{"entity":{"id":"nct07327034","kind":"trial","name":"ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression","aka":[],"tldr":"A phase 2 trial of ABSK-011+BSC in hepatocellular carcinoma, run by Abbisko Therapeutics Co, Ltd, now recruiting.","summary":"ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression is a phase 2 interventional study registered as NCT07327034 by Abbisko Therapeutics Co, Ltd, with 141 participants planned, started 2025-06-13 and due to reach its primary completion in 2027-06-30. Interventions recorded: ABSK-011+BSC and Placebo+BSC.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07327034","url":"https://clinicaltrials.gov/study/NCT07327034"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc","hcc-advanced"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["abbisko"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07327034","phase":"2","setting":"A Randomized, Double-blind, Multi-center, Phase 2 Study to Assess the Efficacy and Safety of ABSK-011 Plus Best Supportive Care (BSC) vs. Placebo Plus BSC in Previously Systemically Treated Advanced or Unresectable Hepatocellular Carcinoma Patients With FGF19 Overexpression","sponsor":"Abbisko Therapeutics Co, Ltd","participation":[{"nct":"NCT07327034","source":"https://clinicaltrials.gov/study/NCT07327034","fetchedAt":"2026-10-07T16:55:41.039Z","studySha256":"999c9b3ec9dd9ac15ca0108a3eddf7e14baeac9c29e4739ae5bc8b44c871620f","overallStatus":"RECRUITING","lastUpdatePosted":"2026-01-08","leadSponsor":"Abbisko Therapeutics Co, Ltd","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":141,"enrolmentType":"ESTIMATED","siteCount":51,"recruitingSiteCount":49,"countries":["China"]}],"started":"2025-06-13","startedType":"actual","enrolled":141,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07327034/","neighbours":{"cancer":[{"id":"hcc-advanced","kind":"cancer","name":"Advanced hepatocellular carcinoma (BCLC C)","route":"/cancers/hcc-advanced/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"company":[{"id":"abbisko","kind":"company","name":"Abbisko Therapeutics","route":"/companies/abbisko/"}],"target":[{"id":"fgf19","kind":"target","name":"FGF19","route":"/targets/fgf19/"}]}}